Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 6/20 | 0.34 |
| ▸ | FPR2 | P25090 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.32 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22759432 | 0.80 | PPIA (0.35) | FPR3FPR2AAK1BACE1NR1H2 | |
| SCHEMBL29237103 | 0.79 | DRD2 (0.41) | FPR3FPR2DRD2 | |
| SCHEMBL22759401 | 0.79 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL28699281 | 0.77 | CAMK2D (0.45) | FPR3FPR2DRD2 | |
| SCHEMBL22759741 | 0.75 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL4610689 | 0.74 | FPR2 (0.38) | FPR2NR1H2 | |
| SCHEMBL22759433 | 0.72 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL21587688 | 0.70 | AAK1 (0.41) | AAK1 | |
| SCHEMBL22759740 | 0.70 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL19224563 | 0.70 | TNF (0.36) | FPR3FPR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-117486888-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117486890-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113966336-B | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-3980424-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | Hutchison Medipharma Limited (CN) | 2022-04-13 | — | — | EP | disclosed |
| CN-113966336-A | Tricyclic compound and use thereof | 和记黄埔医药（上海）有限公司 | 2022-01-21 | — | — | CN | disclosed |
| WO-2020244637-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | CYP2C8, CYP11B2, CYP3A7 | FPR3 2597/4885FPR2 3067/4885CA1 2243/4885 |
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | FPR3 2597/4885FPR2 3067/4885CA1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.